Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis
- 22 Sep 2017 Planned End Date changed from 15 Apr 2018 to 31 Oct 2017.
- 22 Sep 2017 Planned primary completion date changed from 15 Apr 2018 to 31 Oct 2017.
- 08 Sep 2016 Status changed from recruiting to active, no longer recruiting.